At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
NKTR Nektar Therapeutics
Market Closed 09-25 16:00:00 EDT
57.06
-2.32
-3.91%
盘后57.06
+0.000.00%
19:30 EDT
High60.98Low57.04Vol2.64M
Open59.77D1 Closing59.38Amplitude6.64%
Mkt Cap1.95BTradable Cap1.63BTotal Shares34.14M
T/O153.51MT/O Rate9.24%Tradable Shares28.53M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Nektar Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
THOMSON REUTERS  ·  04:15
Nektar Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
U.S. Stocks on the MOVEx-Microsoft, Nike, Nektar Therapeutics
Reuters  ·  00:39
U.S. Stocks on the MOVEx-Microsoft, Nike, Nektar Therapeutics
Top Midday Stories: Akamai's $11.6 Billion Anthropic Deal; Scholastic Q1 Loss Widens; Nektar Awarded $90 Million in Eli Lilly Case
MT Newswires Live  ·  00:05
Top Midday Stories: Akamai's $11.6 Billion Anthropic Deal; Scholastic Q1 Loss Widens; Nektar Awarded $90 Million in Eli Lilly Case
Nektar Therapeutics Price Target Maintained with a $178.00/Share by BTIG
Dow Jones  ·  09-25 22:42
Nektar Therapeutics Price Target Maintained with a $178.00/Share by BTIG
Sector Update: Healthcare Stocks Edge Higher Premarket Friday
MT Newswires Live  ·  09-25 21:19
Sector Update: Healthcare Stocks Edge Higher Premarket Friday
Jury Finds Lilly Breaches Implied Covenant in Rezpegaldesleukin License, Awards Nektar USD 90 Million Plus Interest
Reuters  ·  09-25 19:01
Jury Finds Lilly Breaches Implied Covenant in Rezpegaldesleukin License, Awards Nektar USD 90 Million Plus Interest
Nektar Therapeutics - Jury Finds Lilly Breached Implied Covenant of Good Faith in License Agreement - SEC Filing
THOMSON REUTERS  ·  09-25 19:01
Nektar Therapeutics - Jury Finds Lilly Breached Implied Covenant of Good Faith in License Agreement - SEC Filing
Nektar Therapeutics - Jury Awards Nektar Therapeutics $90 Mln in Damages Plus Interest - SEC Filing
THOMSON REUTERS  ·  09-25 19:01
Nektar Therapeutics - Jury Awards Nektar Therapeutics $90 Mln in Damages Plus Interest - SEC Filing
Nektar shares pressured by jury notes in Lilly case, says B. Riley
TIPRANKS  ·  09-23
Nektar shares pressured by jury notes in Lilly case, says B. Riley
Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (KYMR), Vertex Pharmaceuticals (VRTX) and Nektar Therapeutics (NKTR)
TIPRANKS  ·  09-23
Analysts Offer Insights on Healthcare Companies: Kymera Therapeutics (KYMR), Vertex Pharmaceuticals (VRTX) and Nektar Therapeutics (NKTR)
Nektar Therapeutics is Maintained at Neutral by Wedbush
Dow Jones  ·  09-23
Nektar Therapeutics is Maintained at Neutral by Wedbush
Wedbush Cuts Price Target on Nektar Therapeutics to $50 From $80, Keeps Neutral Rating
MT Newswires Live  ·  09-23
Wedbush Cuts Price Target on Nektar Therapeutics to $50 From $80, Keeps Neutral Rating
Nektar Therapeutics : Wedbush Cuts Target Price to $50 from $80
THOMSON REUTERS  ·  09-23
Nektar Therapeutics : Wedbush Cuts Target Price to $50 from $80
Nektar Therapeutics Price Target Maintained with a $178.00/Share by BTIG
Dow Jones  ·  09-16
Nektar Therapeutics Price Target Maintained with a $178.00/Share by BTIG
Nektar Therapeutics Price Target Maintained with a $178.00/Share by BTIG
Dow Jones  ·  09-09
Nektar Therapeutics Price Target Maintained with a $178.00/Share by BTIG
Nektar Therapeutics - Enters Quiet Period Beginning Sept 8, 2026 Until Phase 2B Rezolve-Aa Study Data - SEC Filing
THOMSON REUTERS  ·  09-09
Nektar Therapeutics - Enters Quiet Period Beginning Sept 8, 2026 Until Phase 2B Rezolve-Aa Study Data - SEC Filing
Peer‑Reviewed REZOLVE‑AD Phase 2b Data Could Be A Game Changer For Nektar Therapeutics (NKTR)
Simply Wall St.  ·  08-31
Peer‑Reviewed REZOLVE‑AD Phase 2b Data Could Be A Game Changer For Nektar Therapeutics (NKTR)
Nektar Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Reuters  ·  08-29
Nektar Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Nektar Grants Inducement Equity Awards to New Hires, Including Options Priced at USD 74.53
Reuters  ·  08-29
Nektar Grants Inducement Equity Awards to New Hires, Including Options Priced at USD 74.53
Nektar Therapeutics - Rezolve-Ad Study Meets All Primary and Key Secondary Endpoints for Rezpegaldesleukin 24 ΜG/Kg Q2w
THOMSON REUTERS  ·  08-25
Nektar Therapeutics - Rezolve-Ad Study Meets All Primary and Key Secondary Endpoints for Rezpegaldesleukin 24 ΜG/Kg Q2w

Introduction

Company Name.
Nektar Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 1B clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1/2 clinical trial for the treatment of non-Hodgkin's lymphoma and multiple myeloma, and head and neck cancer squamous cell carcinoma and colorectal cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Baxalta Incorporated; Eli Lilly and Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
Issue price:
--